Answers are grounded in this paper and cite their sources.
Background and Objectives: Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive disease, and the survival benefit of adding immune checkpoint inhibitors (ICIs) to first-line chemotherapy is modest and heterogeneous; simple, accessible prognostic markers are therefore needed. We evaluated composite risk scores combining pretreatment positron emission tomography (PET)-derived metabolic tumor burden with systemic inflammatory markers in this setting. Materials and Methods: This single-center retrospective cohort study included 112 consecutive patients diagnosed between January 2019 and December 2025. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on pretreatment 18F-fluorodeoxyglucose PET/computed tomography were combined with one of three blood-based inflammatory markers: neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) or systemic immune–inflammation index (SII). Each component was scored 0 or 1 at the cohort median, yielding three risk scores of 0–3 points (RS1, NLR-based; RS2, PLR-based; RS3, SII-based) and low-, intermediate- and high-risk groups. Progression-free survival (PFS) and overall survival (OS) were analyzed with the Kaplan–Meier method, the log-rank test and separate multivariable Cox models for each score adjusted for performance status and liver and bone metastases; incremental value was assessed with Harrell’s concordance index (C-index). Results: Median PFS was 7.70 months and median OS was 14.43 months, with a median follow-up of 27.6 months. All three scores stratified PFS and OS in univariable analysis (RS1: p = 0.008 and p = 0.002, respectively). RS1 was the only score independently associated with both outcomes (PFS: hazard ratio [HR] per risk tier 1.39, 95% confidence interval [CI] 1.04–1.86, p = 0.026; OS: HR 1.53, 95% CI 1.09–2.16, p = 0.014). RS2 and RS3 were not independently significant. RS1 modestly improved the C-index of clinical factors (by approximately 0.02), but NLR added no significant information beyond metabolic burden. Conclusions: A composite score combining PET-derived metabolic burden with NLR was independently associated with survival in ES-SCLC treated with chemoimmunotherapy, but its added discrimination was modest and driven mainly by the metabolic component; these exploratory findings require prospective validation.
No takes yet. Share an insight, caveat, or question.
Özçelik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: